Recent Updates
Recently added Catalysts
DMAC Positive Sentiment

DiaMedica Therapeutics to Present at Lake Street’s 3rd Annual Best Ideas Growth (BIG3) Conference on September 12, 2019

Key Takeaway: DiaMedica Therapeutics Inc. will participate in the Lake Street Capital Markets 3rd Annual Best Ideas Growth Conference on September 12, 2019. CEO Rick Pauls will engage in one-on-one meetings with investors throughout the day. The conference aims to connect institutional investors with dynamic public growth companies.

Market Sentiment Analysis

POSITIVE FACTORS

  • DiaMedica will showcase its growth potential at a prominent investor conference.
  • The event allows for direct engagement with institutional investors.
  • DiaMedica is actively developing treatments for significant health issues.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~16 mo
Low dilution risk
Lead asset
Recombinant human tissue kallikrein
Phase 2 · Acute Ischemic Stroke

Full Press Release Details

MINNEAPOLIS, Sept. 06, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that management will attend the Lake Street Capital Markets 3rdAnnual Best Ideas Growth (BIG3) Conference on Thursday, September 12th, 2019, at the Parker New York in New York City.
DiaMedica’s President and Chief Executive Officer, Rick Pauls, is scheduled to meet with investors on Thursday, September 12th, with one-on-one meetings to be held throughout the day.
About the BIG3 ConferenceLake Street will host its third annual B.I.G. (Best Ideas Growth) institutional investor conference at the Parker New York, showcasing many interesting, dynamic public growth companies. Executives from approximately 65 publicly traded companies will meet institutional investors in an interactive, one-on-one meeting format. This is an invitation-only event attended by top institutional investors from across the country.
For more information, visithttps://www.lakestreetcapitalmarkets.com/big3conferenceor contact your Lake Street representative or email conference@lakestreetcm.com.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. The Company currently has an ongoing phase II study in acute ischemic stroke and a phase Ib study in chronic kidney disease. DiaMedica’s shares are listed on The Nasdaq Capital Market under the trading symbol “DMAC.”

For more information, please visitwww.diamedica.comor follow us onTwitter.Contact:

Frequently Asked Questions

When is DiaMedica presenting at the conference?

DiaMedica will present at the Lake Street BIG3 Conference on September 12, 2019.

Who is the CEO of DiaMedica Therapeutics?

Rick Pauls is the President and Chief Executive Officer of DiaMedica.

What type of company is DiaMedica Therapeutics?

DiaMedica is a clinical stage biopharmaceutical company focused on chronic kidney diseases and neurological disorders.

What is the format of the BIG3 Conference?

The BIG3 Conference features one-on-one meetings between executives and institutional investors.

Last updated: Sep 6, 2019